Evidence map›Paper›PMID 31646150›Full record

ArticleMicrobial cell (Graz, Austria)2019

Inhibiting eukaryotic ribosome biogenesis: Mining new tools for basic research and medical applications.

Lisa Kofler, Michael Prattes, Helmut Bergler

Abstract readComment
In one paragraph

Article in Microbial cell (Graz, Austria), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Lisa KoflerInstitute of Molecular Biosciences, University of Graz, NAWI Graz, Humboldtstraβe 50-EG, A-8010 Graz, Austria.
Michael PrattesInstitute of Molecular Biosciences, University of Graz, NAWI Graz, Humboldtstraβe 50-EG, A-8010 Graz, Austria.
Helmut BerglerInstitute of Molecular Biosciences, University of Graz, NAWI Graz, Humboldtstraβe 50-EG, A-8010 Graz, Austria.

Funding

Austrian Science Fund FWF P 26136Austrian Science Fund FWF P 27996Austrian Science Fund FWF P 28874Austrian Science Fund FWF P 29451Austrian Science Fund FWF P 32536
6 · The paper itself

Abstract

The formation of new ribosomes is a fundamental cellular process for each living cell and is tightly interwoven with cell cycle control and proliferation. Minimal disturbances of this pathway can result in ribosomopathies including an increased risk for certain cancer types. Thus, targeting ribosome biogenesis is an emerging strategy in cancer therapy. However, due to its complex nature, we are only at the beginning to understand the dynamics of the ribosome biogenesis pathway. One arising approach that will help us to embrace the tight timely cascade of events that is needed to form a new ribosome is the use of targeted chemical inhibition. However, only very few specific chemical inhibitors of the ribosome biogenesis pathway have been identified so far. Here we review our recently published screen to identify novel inhibitors of the ribosome biogenesis pathway in yeast (Awad

Indexed as

high-throughput screenInhibitorsribosome biogenesisrRNA processingyeast

Identifiers

PMID31646150
PMCPMC6780010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.